Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
about
Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesMonoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target DrugsGenetic Approaches to Hypothalamic-Pituitary-Adrenal Axis RegulationDrugQuest - a text mining workflow for drug association discoveryIs there an association between diet and depression in children and adolescents? A systematic review.Medical Yoga Therapy.Abnormalities of serotonergic neurotransmission in animal models of SUDEP.The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.Neuropathic pain promotes adaptive changes in gene expression in brain networks involved in stress and depressionNew targets for rapid antidepressant action.M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the HippocampusCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsTowards the Molecular Foundations of Glutamatergic-targeted Antidepressants.Five potential therapeutic agents as antidepressants: a brief review and future directions.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression5-Hydroxytryptophan, a precursor for serotonin synthesis, reduces seizure-induced respiratory arrest.Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.Computational and biological evidences on the serotonergic involvement of SeTACN antidepressant-like effect in mice.TRPC Channels and Mental Disorders.Differences between adolescents and adults in the acute effects of PCP and ketamine and in sensitization following intermittent administration.MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action.Antidepressant-Like Effect of Lipid Extract of Channa striatus in Postpartum Model of Depression in Rats.Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder.Efficacy of antidepressants: bias in randomized clinical trials and related issues.Aripiprazole-induced sleep-related eating disorder: a case report.Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors.Chronic Stress Disturbs Metabolome of Blood Plasma and Urine in Diabetic RatsRepurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor AntagonistsNa⁺, K⁺-ATPase Signaling and Bipolar Disorder
P2860
Q28066691-61288883-77DA-4CFF-9A95-CB799702465EQ28074736-13A754FE-E3BF-4337-8F3A-C10E20E1B846Q28082581-A4673FD2-A2D9-4862-BB23-C17CE0A07712Q28830509-C5B23AD8-B5EB-4CE6-8C20-D7699A5D630EQ30238984-DB2C6FAC-69C1-4519-B079-CBAB62366CC2Q30274750-49B77EE6-E9AA-43E2-9F41-BA82278C754FQ30363561-D6BABFB5-BE9C-42DB-BB19-E100153E05BFQ33863747-800505E4-4147-4EBA-8BC2-EA414F9052DAQ33925526-87432FA9-0392-4D0F-A926-F1A5B498D274Q34507177-02B8B981-EF04-46C5-9CDD-2339C46B855AQ36199834-6C5F797F-1DB1-4E76-9068-4A87D0F9EC42Q37197216-8276AFFC-A9C7-40AA-AD18-8700E1C8B2BAQ37668029-AC0206D8-A1D5-42AE-9D7E-8345D92EF2D9Q38574831-2BBBB8A6-7C8F-4D58-80EB-C5DEB24DAD93Q38990885-7CC3C2C8-3170-44A3-BB3D-6F4403084C1BQ39682935-EFF3FB62-1B99-4BE2-8896-4CE039A4B003Q42253330-2A6251F3-B0A7-49D5-9A4D-C5B95E327CC2Q46106508-76CCED15-5781-42D9-803E-8FEB2BEC0425Q46351373-AD9A2BFD-8852-415A-8C2A-B1A02AFABD3CQ46530600-8017E7F5-40F0-44F0-B0F2-EBFAAA07080FQ47118154-4E461EA7-F393-4E11-8739-4B29A96B722DQ47556012-870AA6F7-6B47-4A5E-A2DA-DE3632939B72Q47732078-BCDB0ED0-7742-49F0-AADF-CCA77E028BB4Q47772123-100E3A02-D326-4B1C-B4EB-6047C2F81C73Q52604127-86AA49EB-6CF0-40D3-85D8-01FC6EAFE2BFQ53401817-BB729317-1DAC-4349-BA34-516752E8B409Q58573891-F8A04970-AC79-46BF-9657-5961BA6A9618Q58581253-D2078D9C-1FAB-4723-A29A-910EB6F4B420Q58796804-7F3EA1E1-16C9-4F6C-AA0F-7D3389517114
P2860
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@ast
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@en
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@nl
type
label
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@ast
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@en
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@nl
prefLabel
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@ast
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@en
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@nl
P3181
P1476
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
@en
P2093
Connie Sánchez
Elena Dale
P3181
P356
10.1016/J.BCP.2015.03.011
P407
P577
2015-05-15T00:00:00Z